- FDA’s Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc’s (NASDAQ:YMAB) potential pediatric neuroblastoma treatment, omburtamab.
- The adcomm voted 16 to 0 that the company had not provided sufficient evidence to conclude that omburtamab improves overall survival.
- The FDA noted that the entire application for 131I-omburtamab is based on a small, single-arm trial from New York’s Memorial Sloan Kettering (MSK) Cancer Center that found the three-year overall survival rate after CNS/LM relapse in the efficacy population of 94 patients was 54%.
- “OS should generally be evaluated in randomized trials because data from externally controlled trials may not be reliable or interpretable,” FDA wrote in its briefing document.
- Related: Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer.
- The agency also noted that patients in the 131I-omburtamab study received multimodality treatment for CNS/LM relapse before the investigational drug “that was generally more intensive than treatment documented in the external control population,” FDA said.
- There is a clear trend toward improved survival with higher treatment intensity in the external control population.”
- ODAC reviewed data from omburtamab’s clinical development program with a focus on study 03-133 (a pivotal phase 1 study) and study 101 (a pivotal phase 2 study), as well as the historical control group.
- Y-mAbs marketing application for omburtamab was accepted for Priority Review by the FDA, with a PDUFA target date of November 30.
- Price Action: YMAB shares traded lower by 36.62% at $5.66 in premarket on the last check Monday.
Dollar General May Have Reported Solid Q3 Performance, But This Analyst Cautions “The Path Could Be Bumpy” Ahead
Telsey Advisory Group analyst Joseph Feldman reiterated the Market Perform rating on Dollar General Corporation (NYSE: DG),
